샘플 요청 목록

 카트 문의
시장보고서
상품코드
1644234

세계의 방사선 치료학 시장

Radiotheranostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 168 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 방사선 치료학 시장은 2030년까지 224억 달러에 달할 전망

2024년에 104억 달러로 추정되는 세계의 방사선 치료학 시장은 분석 기간인 2024-2030년에 CAGR 13.6%로 성장하며, 2030년에는 224억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 표적 진단 모달리티는 CAGR 7.5%를 기록하며, 분석 기간 종료까지 98억 달러에 달할 것으로 예측됩니다. 표적 치료제 부문의 성장률은 분석 기간 중 CAGR 20.5%로 추정됩니다.

미국 시장은 27억 달러로 추정, 중국은 CAGR 13.0%로 성장 예측

미국의 방사선 치료학 시장은 2024년에 27억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 35억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 13.0%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 11.7%와 12.1%로 예측됩니다. 유럽에서는 독일이 CAGR 10.4%로 성장할 것으로 예측됩니다.

세계의 방사선 치료학 시장 - 주요 동향과 촉진요인 정리

방사선 치료학을 정밀의료의 최전선으로 끌어올린 요인은 무엇인가?

영상 진단과 표적 방사선 치료를 결합한 최첨단 접근 방식인 방사선 치료는 맞춤형 의료의 게임 체인저로 부상하고 있습니다. 이 이중 기능 기술은 종양의 정확한 식별과 방사성 의약품을 이용한 맞춤형 치료를 가능하게 하여 건강한 조직에 대한 손상을 최소화할 수 있도록 돕습니다. 전 세계에서 암 발병률이 지속적으로 증가하고 있는 가운데, 방사선 치료는 보다 효과적이고 덜 침습적인 치료법을 제공할 수 있다는 점에서 각광을 받고 있습니다. 또한 방사선 치료와 핵의학의 통합은 종양학에 혁명을 일으켜 환자들에게 더 나은 치료 결과와 삶의 질을 제공할 수 있습니다. 정밀의료로의 전환이 진행되면서 방사선 치료는 암과 싸우는 데 있으며, 매우 중요한 툴이 되고 있습니다.

기술 혁신은 방사선 치료학의 범위를 어떻게 재정의하고 있는가?

기술의 발전은 방사선 치료의 역량을 확장하는 데 있으며, 핵심적인 역할을 하고 있습니다. 루테튬-177이나 악티늄-225와 같은 방사성동위원소와 같은 새로운 방사성 의약품의 개발은 영상 진단과 치료 모두에서 더 높은 정확도를 가능하게 하고, PET/CT나 SPECT/CT와 같은 분자 이미징 기술의 발전은 질병 진단과 치료 모니터링의 정확도를 향상시키고 있습니다. 향상시키고 있습니다. 또한 인공지능과 머신러닝이 방사선 치료 워크플로우에 통합되어 이미지 해석을 강화하고 치료 계획을 최적화하고 있습니다. 이러한 기술 혁신은 임상적 성공을 촉진할 뿐만 아니라, 제약회사와 연구기관이 방사선 치료학 개발에 많은 투자를 하도록 유도하고 있습니다.

방사선 치료학의 새로운 응용 및 동향은?

전립선암과 신경내분비종양 치료에 큰 성공을 거둔 종양학 분야 외에도 방사선 치료의 용도가 빠르게 확대되고 있습니다. 연구자들은 특정 생물학적 경로를 표적으로 삼는 능력을 활용하여 심혈관계 질환이나 특정 감염성 질환과 같은 다른 질병을 치료할 수 있는 가능성을 모색하고 있습니다. 새로운 동향으로는 면역요법이나 화학요법과 결합하여 치료 효과를 높이는 병용요법이 있습니다. 또한 방사성 의약품 생산 및 공급망 물류의 발전은 확장성 문제를 해결하고 다양한 의료 환경에서 이러한 치료법이 더 많은 환자들에게 제공될 수 있도록 보장하고 있습니다.

방사선 치료학 시장의 급성장 원동력은?

방사선 치료 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 전 세계에서 암 발병률이 증가함에 따라 혁신적인 치료법에 대한 수요가 증가하고 있으며, 방사선 치료는 중요한 관심 분야로 부상하고 있습니다. 방사성 의약품 개발 및 분자 이미징 기술의 상당한 발전은 이러한 치료법의 효과와 접근성을 향상시키고 있습니다. 핵의학 인프라에 대한 투자 증가와 신흥 국가 시장의 의료 예산 확대도 시장 성장을 가속화하고 있습니다. 또한 환자 및 의료 서비스 프로바이더 사이에서 개인화된 치료 접근 방식을 선호하는 경향이 높아지면서 방사선 치료의 채택을 촉진하고 있습니다. 규제 당국의 지원과 유리한 상환 정책은 이 유망한 기술의 보급에 더욱 기여하고 있으며, 정밀의료의 미래에서 그 역할을 확고히 하고 있습니다.

부문

양식(표적진단제, 표적치료제); & 방사성동위원소(루테튬-177 방사성동위원소, 갈륨-68 방사성동위원소, 요오드-131 방사성동위원소, 요오드-123 방사성동위원소, 기타 방사성동위원소); & 용도(종양학 응용, 비종양학 응용, 비항암 응용) 종양학 응용, 비종양학 응용, 종양학 응용)

조사 대상 기업의 예(주목 36사)

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.02.28

Global Radiotheranostics Market to Reach US$22.4 Billion by 2030

The global market for Radiotheranostics estimated at US$10.4 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Targeted Diagnostics Modality, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Targeted Therapeutics Modality segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.0% CAGR

The Radiotheranostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Radiotheranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Radiotheranostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Focus on Precision Medicine and Targeted Therapies Drives Market Growth
    • Rising Adoption of Theranostic Agents in Oncology Treatments Propels Industry Expansion
    • Growing Use of PET Imaging in Radiotheranostic Applications Fuels Demand
    • Expansion of Nuclear Medicine Facilities Supporting Radiotheranostics Enhances Market Potential
    • Advancements in Radiolabeling Technologies for Improved Accuracy Propel Technological Growth
    • Integration of AI Tools in Radiotheranostic Imaging and Diagnostics Drives Innovation
    • Increasing Demand for Personalized Treatment Protocols in Cancer Care Boosts Adoption Rates
    • Collaboration Between Pharmaceutical and Diagnostic Companies in Radiotheranostics Drives Market Expansion
    • Role of Radiotheranostics in Emerging Immuno-Oncology Treatments Fuels New Opportunities
    • Rising Utilization of Theranostics for Non-Oncological Conditions Enhances Market Demand
    • Growing Interest in Dual-Modality Imaging Techniques Drives Technological Advancements
    • Investments in R&D for Novel Radiotheranostic Compounds Propel Industry Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Radiotheranostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Targeted Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lutetium-177 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Lutetium-177 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gallium-68 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Gallium-68 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Iodine-131 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Iodine-131 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Iodine-123 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Non-Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • JAPAN
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CHINA
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • EUROPE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • FRANCE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • GERMANY
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제